<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 340 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page339.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=340">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 340 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 340</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=340"><img src="../thumb/340.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Endocrine System - 19.6.2 / 19.6.3                                             2020-04 / 303
       Indications: Uter.dysfunct.bleed.when all organ. caus.ruled out   Contraindications: Known/susp./hist.of breast Ca, known/susp.  Side effects: Signific.bone miner.density loss, anaphylact./ana-
       as poss.aetiolog.fact.        oestrog.depend.neoplas., undiagn. genit. bleed., untreat.endometr.  phylactoid reacts./angio-oed., suppress. adren.funct., menstr.bleed.
       (S4) IV INJ. G3017.           hyperplas., prev./ curr. ven.thrombo-embol., known thrombophil.   chang., weight chang., vaginit., fluid retent., Cushingoid sympts.,
       756784-018: 25 mg, 5 ml, R353,64  disords., act./recent arter.thromboembol.dis., ac. liv. dis/hist.thereof   decr.libido/anorgasm., CNS eff.incl. somnol.& convuls., hot flush.,
       Dosage: Short term use only. Admin.IV/IM.& at low.dos. accord.to   as long as LFT fail.return.to norm., porphyr., pregn./susp., lactat.  thrombo-embol.dis., abdom.pain/discomf., GI disturbs., jaund., dis-
       clinic.respons. Admin.IV inj. slow. Adults: 25 mg.   Side effects: Common: Genit. candidias./vaginit., headache,   turb. liv.funct., rash, acne, alopec., hirsut., prurit., urticar., backache,
       Emerg.spont.capill.bleed.contr.: 1 inj.immed., rep.hrly.up to   naus., abdom.pain/-distens./-discomf., dyspeps., vomit., flatul.,   musc./leg cramps, osteoporos.& relat. fract, arthralg., amenorrh.&
       3 doses.                      vag.haemorrh./-disch./ discomf., breast oed./-enlargem./-pain/-  anovulat., leucorrh., mastodyn., breast tendern., dysmenorrh., galac-
       (S4) TABS, [P/S] G/21.8.1/3016, 15, 14  tendern., periph.oed. Uncommon: Hot flush, hypertens., rash,   torrh., chang.in cervic.eros.& secret., virilisat., feminisat., pelvic pain,
       Indications: Oestr.replacem.ther., path.states of reproduct.endocr.  weight incr. Unknown: Benign/ malign. oestrog-depend.neoplasms   asthen., fatig., pyrex., inj.site.reacts., decr.gluc.tol.
       imbal., climacter.& menopaus. sympts., osteoporos.induc.by oestrog.-  eg.endometr Ca, gen. hypersens., fluid retent., insomn., depress.,   Warnings and special precautions: Loss of BMD in adolesc./
       defic.in conjunct. with other meas., fem.castrat., prim. ovar. fail.,   migraine aggravat., DVT, diarrh., urticar., rash erythemat., prurit. rash,   early adulthood & pre-menopaus. women theref.consid.risk/be-
       amenorrh., fem.hypogenital., hypogonad., palliat.of inop.prostat.Ca   genit.prurit., endometr. hyperplas., vag.irrit./-pain/-ulcerat., vaginis-  nef.assessm., bone loss is &gt; with incr.durat.& compl.revers.may
       & mamm.Ca in women who are post menopaus.for a min.of 5 yrs  mus, medicine ineffect., incr.weight/-bld.oestrog., MI, stroke, gall   not be poss., risk benef.analys.in women with osteoporot./ oste-
       756725-038: 0,3 mg, 28, R133,85  bladd.dis., chloasma, erythema multiforme/ nodosum, vasc.purpura,   oporos.risk fact., adeq.Ca.& vit.D intake recomm., developm.of
       756733-030: 0,625 mg, 28, R156,18  prurit., epilep., libido disord., asthma deteriorat., probable dementia.  thrombo embol.S&S, ophthalm. eval.if vis.disturbs.exper., when
       756741-033: 1,25 mg, 28, R185,00  Warnings and special precautions: Compl. physic./ med./   treat. cert. cancers cortic.-like activ.report.with the very high dos.,
       Dosage: Admin.contin.or cyclic: 3 wks.on,1 wk. off. Init.ther.at low.  fam.hist. bef.ther.init./re-institut. & re-assess. ther.at least once/  progestat.agent.dur.pregn.not recomm., diabet., poss.masks onset
       effect.dos.& for short.durat.   yr.with phys.incl. gynae. exam., reg.breast exam./mammogr.advoc.,   of climacter., liv.dis./ dysfunct., not recomm.for second.amenorrh./
       For women with intact uterus add progestogen for 10-14 days each   endometr. hyperplas. hist.from prev.unoppos. oestrog. treatm., excl.  dysfunct. uter.bleed., hypercalcaem., condit.affect. by fluid retent.,
       month in contin.ther.         poss endometr. hyperstimulat./ malign.bef.init.ther., incr.breast Ca   Cushingoid sympts.in high dos., investig. abnorm.bleed., ment.de-
       Climacter./sympts: Vasomot.sympts.& atroph. vaginit: 0,3-1,25 mg   risk with syst.ther., syst.HRTassoc.with high ven. thromboembol.   press.hist., menstr. cycle disrupt., physic.examin.pts bef. treatm. with
       dly. Re-eval.necessit.        risk, VTE/ stroke/ovar.Ca risk fact., discont.ther.if VTE devel.,   specif.ref.to breast & pelvic organs as well as pap.smear, excl.or-
       Osteoporos.prev.& managem: 0,625-1,25 mg dly.depend.on re-  condits.poss.recur/ aggrav: leiomyoma/ endometrios./hist.of or   gan.causes if bleed. irreg., adeq.diagn.meas.indicat.for undiag.vag.
       spons.admin.contin./cyclic.as 25 days on & 5 days off.  risk facts. for thromboembol.disords./hypertens./ liv. disords./ diab.  bleed., cert.lab.endocr.& poss.liv.funct.tests poss. affect., in oncolog.
       Fem. hypogonad:  1,25-7,5 mg dly cyclic.for 3 wks. on & 1 wk.off.   mellit.with/without vasc.involvem./ cholelithias. /migraine or sev.  indicat.may caus.part.adren. insuff. dur. metyrapone test., overall
       Indiv.accord.to respons. Titr. upward grad.at 6-12 mnth interv.as   headache/SLE/ epilep./ asthma/ otoscleros., discont.ther.in case of   slight /no incr. breast Ca risk, consid.not re-admin.if jaund. devel.,
       necess.to achieve appropr.bone age advancem.& event. epiphys.   jaund./ liv.funct.deteriorat./signif.BP incr/ new onset migraine-type   no protect.against HIV(AIDS) infects./other STD’s
       clos. Chron.dos.of 0,625 mg with sequent. progest.suffic.to induc.  headache & pregn., limit. exper. in women over 65 yrs., only use/  Drug interactions: Bioavailabil.depress.by aminoglutethimide.,
       artific.cycl.menses.& maint. bone min.density. Maint: Low effect.dos.  contin.as long as benef.outweigh risk.(assess anually), card./ ren.   decr.serum oestrog.lev., ACTH & hydrocortis.bld.lev.poss.decr.
       Female castrat.& prim.ovar.fail: 1,25 mg dly. cyclic. Indiv.ac-  dysfunct., poss.syst.absorpt., incr.risk of probable dement.in pts.&gt;65
       cord.to sev.of condit.& respon. Maint: low.level provid.effect.control.  start ther., lact.intol.  DIANE-35, Bayer (Pty) Ltd
       Palliat.prostat.Ca: 1,25-2,5 mg 3xdly.                     See Section 14.6
       Palliat.of mammary.Ca: Up to 10 mg 3xdly for at least 3 mnths.  GINETTE, Cipla Medpro (Pty) Ltd
       Contra-indications: Known /suspect.pregn., liv.dysfunct./dis.
       where liv. funct. tests fail to return to norm., undiagn.abnorm.genit.  19.6.3  Progestogens  See Section 14.6
       bleed., known/ susp./hist of breast Ca, suspect.oestrog.depend.      (See also 19.6.4)  HEXAL-MPA 5, 10, Sandoz [P/S]
       neoplas., act./ past hist.of confirm.ven. thromboembol., act./rec.  Medroxyprogesterone acetate.
       arter.thromboembol.dis., HRT should not to be init./cont.to prev.  CRINONE (MDR Listing)  Indications: Dysfunct.uter.bleed., mild to mod. endometr., op-
       coron.heart dis., lactat., safety & effic.in paed. pts. not est., Tabs   CRINONE 8%, (Biopharma Div) Merck [P/S] &  pose endometr.eff.of oestrog.in menopaus. women being treat.
       also: Endometrois., endometr.Ca.  Progesterone             with oestrog., menopaus. vasomot.sympts., diagnos.of prim.&
       Side-effects: Abnorm.uter.bleed., vis. abnorm. incl.retin.vasc.  Indications: Progesterone supplementat./ replacem.in assist.  second.amenorrh.
       thrombos., hot flush., vag.bleed., breast tendern.& enlargem., dis-  reproduct.technology of infert. women with progesterone defic.  (S4) TABS, 38/21.8.2/0188, 0189
       charge, breast pain, dysmenorrh., galactorrh., incr.uter. leiomyomata   (S4) VAG.GEL, A38/21.8.2/0615  706704-001: 5 mg, 30, R124,65
       size, endometr. hyperplas., GI disturbs., pancreatit., headache, mi-  705334-001: 90 mg/dos., 15 applicat., R628,92  705705-001: 10 mg, 30, R188,40
                                                                                          th
                                                                                            st
       graine, dizzin., nervousn., pulm.embol., ven. thromboembol., su-  Dosage: 1 intravag.applicat.dly start.aft. document. ovulat/arbitrar.  Dosage: Dysfunct.uterine bleed: 5-10 mg dly. from 16 -21  day
       perfic.thrombophlebit., hypotens., oed., skin reacts.incl.erythema   on 18 -21  day of cycle. When used dur.in-vitro fertilisat.cont.dly ap-  of cycle x5-10 days. Use concom. oestrog.if bleed.due to defic.of both
                                       th
                                         st
       multiforme/ nodosum, anaphylact.reacts.incl. angioed., poss. vag.  plicat. x30 days if lab.evid.of pregn.pres.  ovarian hormon. Admin.2 subseq.cycles if bleed.satisfact. control.
       cornific. & bleed./ prem.breast developm. in prepubert.girls, demen-  Contraindications: Undiagn.uter.bleed., known / suspect.breast   Endometrios: 10 mg 3xdly from 1  day of cycle x90 days.
                                                                                 st
       tia, CVA, epilep./chorea exacerbat., arthralg., leg cramps, gallbladd.  or genit.organ malign., porphyr., thrombophlebit./thromboembol.  Opposit.of endometr.eff.of oestrog.in oestrog. treat.meno-
       dis., cholest.jaund., vaginit., MI, gluc. intol., hypocalcaem., contact   disord/cerebr. apoplexy/hist of these condits., miss.abort., liv. dys-  paus.women: 5-10 mg/day from 16 day of a25 day course of
                                                                                   th

       lens intol., weight chang., incr.triglycer., elev.BP, water & Na retent.,   funct./dis., lactat.  oestrog.ther.x10 days.
       epiphys. clos.acceler.with large/rep.dos.over prolong.periods., de-  Side effects: Xeropthalm., conjunctivit., GI disturbs., allergy, genit.  Menopaus: 10-20 mg dly.contin. Progestin withdr.bleed.should oc-
       press., benign & malign.neoplasms, alopec., hirsutism, transit.liv.  monillias., URTI, cystit., UTI, fatig., pain, thirst, asthen., oed., fev.,   cur, begin.on 3  – 7  day post Hexal-MPA treatm.
                                                                         rd
                                                                           th
       funct. value deviat., libido chang., IV also: anaphylactoid. reacts.  influ-like sympts., musculosket.& connect.tiss.disords., incr./decr.  Prim.& second.amenorrh: 5-10 mg dly x10 days.
       incl.urticar., loc. reacts. at inj.site.  appetite, CNS effs., depress., decr. libido, nervousn., sleep disord.,   Contraindications: Thrombophlebit./ thromboembol. disord. /cer-
       Special precautions: Only consid.ther.for osteoporos. in women   emot.liability, aggress. reacts., noctur., dysuria, freq.micturat., perin.  ebr.apoplexy/hist. thereof, breast/genit.malign., undiagn.vag.bleed.,
       at signific.risk & where non-oestrog.meds.not appropr., weigh risk   pain, breast enlargem./pain/tendern., genit. prurit., dyspareunia, vag.  miss./ incompl.abort., liv.dis./dysfunct., pregn.& lactat.
       vs.benef. of HRT incl.emerg.risk with contin.ther., consid.alt.to HRT   discharge/dryn., asthma, dyspnoea, incr.sweat., face oed., acne, skin   Side effects: Anaphylax.& anaphylact.reacts., thromboembol.phe-
       in women without menopaus. sympts./ long-term use, take into ac-  reacts. incl.discolourat., seborrh., hot flushes, spott., vag. irritat.&   nom., CNS effs., urticar., prurit., oed., skin rash, chloasma, hirsut.,
       count warn./precaut.& advers.reacts.assoc.with oral CEE treatm.,   mild applicat.site reacts., decr. gluc.tol.  acne, alopec., naus., menstr.changes, breast tendern., galactorrh.,
       IV inj.to be admin.slow/short-term use only, infus.with other agents   Special precautions: Thrombot.disord.risk fact., monit.for early   changes in cervic.eros.& secret., neonat. jaund., neuro-ocul.les.,
       not recomm., incr. endometr.Ca risk in women with intact uter. esp.   S/S of thrombot.disords.discont. immed.ir pres., do not use other   weight change, pyrex., moon face, cholestat.jaund. Follow.reacts.
       dur.prolong.treatm., incr.Ca breast & ovaries/CV events risk, caref.   concom.loc. intravag. ther.but if necess.allow 6 hr.interv. betw. ap-  in pts. receiv.oestrog.progest.combinat: incr.BP, backache, premenstr-
       observat. of pts.with thromboembol. risk, incr. stroke risk, incr.de-  plicat., gynaecologic.pretreat.examinat., investig. all irreg.vag.bleed.,   like syndr., erythema multiform. & nodosum, libido & appetite chang-
       ment. risk in stud.in women over 65 yrs., compl.med.hist. & physic./  condits.poss. influenc. by poss.fluid retent., advis.patholog.of ther.if   es, haemorrhag. erupt., cystit.-like syndr., alter.of cert. lab results.
       gynae.exam. bef. start.ther., period.exam. advis. incl. yearly breast.  specim. taken, psych.depress.hist., diab.  Special precautions: Discont.at earliest manifestat./ suspicion of
       exam., gallbladd. dis.risk incr., withdr. if exam reveals papilledema/   See also MDR page 491.  thrombot.disords., diab., As report.in WHI incr.risk of MI/stroke/in-
       retin.vasc.les., asthma, epilep., migraine, card./ren.dysfunct., pre-  vas. breast Ca/pulm.embol./& DVT report.in postmenopaus. women
       exist. hypertriglycerid., imp. liv.funct., past.cholestat. jaund.hist.,   CYCLOGEST, (Cipla) Actavis [P/S]  dur.5 yr.treatm.with concom. conjug.equine oestrog 0,625 mg theref.
       endometr.hyperplas., regul.BP monit.., exacerb.asthma/migraine/  Progesterone (natural).  in absence of comparable data risk with other conj. oestr. should.
       epilep./ diab.mellit. with/without vasc.involvem., SLE/hepat. he-  Indications: Progesterone supplementat.in fertilisat. programmes   be assum.similar, discont.if there is sudden part./complete loss of
       mangiom., endometrios./porphyr.exacerbat., sev. hypocalcaem.,   when secret.insuffic.  vis./sudden onset of proptos./ diplop./migraine/ser.depress,, epilep.,
       do not start ther.bef.epiphys. clos. has occur., card./ren.dysfunct.,   (S4) PESS. Z/21.8.2/294.  asthma, card./ren.dysfunct., onset of climateric. poss. mask., break-
                                     810215-004: 200 mg, 15, R327,42
       discont. oestrog.4-6 wks.bef.surg.assoc.with incr. thromboembol.   through bleed.likely when treat. for endometrios., advise patholog.
       risk, non fat.MI/pulm.embol.& thrombophlebit.risk incr.with dos.  Dosage: 200 mg PV dly, may be incr.to 400 mg 2xdly.  of progester. ther. when submitt specimens.
                                     Contraindications: Undiagn.vag.bleed., thrombo-embol.dis-
       of 5 mg conjug. oestrog./day, sev.hypercalcaem. in breast Ca &   Drug interactions: Aminoglutethimide depress. bioavailabil.
       bone metastas. pts., discont. pend.exam.if sudd. vis.loss/proptos./   ord.hist.
                                     Side effects: Early/delay.menstruat., GI disturbs., acne, fluid re-
       diplop. / migraine, hypothyroid., physic.exam.to be perform. once   MINERVA-35, Aspen Pharmacare (Pty) Ltd
       bleed.has been stop.in case of uter. bleed.if hormon. imbal.susp.&   tent., oed., mass gain, allerg.skin rash., urticar., depress., breast   See Section 14.6
                                     & libido chang., jaund.
       appropr.meas.to prev. recurr.once diagn.confirm., IV/IM oestrog. use   MIRENA, Bayer (Pty) Ltd
       to stop bleed.does not precl. other appropr. meas. use, IV also: Do   Special precautions: Hepat.dysfunct., horm. sens. condits., CV /  See Section 17.1.3
                                     ren.impairm., diab.mellit., asthma, epilep., migraine, other condits.
       not init./ contin.HRT to prevent.coron. heart.dis., careful. observat.
       of pts.with thrombot. dis.risk. fact.   aggrav.by fluid retent., depress.  PRIMOLUT N, Bayer [P/S]
       Drug interactions: Poss.reduc.eff.&/chang.in uter. bleed.profile   DEPO-PROVERA 150, Pfizer [P/S]  Norethisterone.
       with strong CYP3A4 induc., incr. plasma conc.with CYP3A4 inhibit.,   Medroxyprogesterone acetate.  Indications: Dysfunct.uterine bleed., amenorrh., menstr.timing,
       poss.reduc.eff. with St John’s wort.  Indications: Endometrios., adjunct.&/palliat therapy in endo-  endometrios.
                                     metrial & ren.Ca.            (S4) TABS. G3124.
       VAGIFEM, (Adcock Ingram) Novo Nordisk [P/S]  (S4) INJ E/21.8.2/114. 150 mg/ml.  757012-019: 5 mg, 30, R28,31
       Estradiol.                    718440-005: 1x1 ml, R37,93   Dosage: Dysfunct.bleed: 1 tab 3xdly x10 days. Cont.treatm.
       Indications: Atroph.vaginit.due to oestrog.defic.  Dosage: Endometriosis: 50 mg wkly/100 mg every 2 wks by   even aft.arrest of bleed.upto tot.30 days for treatm.to be sucessf.
       (S2) VAG.TABS. 47/21.8.1/0166  IMI x6 mnths.               Prev.dysfunct.bleed.recurr: Admin.prophylact. dur. next 3 cycles.1
       721571-001: 10 µg, 18 with applicat., R354,68  Endometr./ren.Ca: Init. 400-1 000 mg IMI/wk. Maint. improvem.  tab.2-3xdly from 19-26  day of cycle.
                                                                            th
       Dosage: Init: 1 tab.intravag.dly x2 wks. Maint: 1 tab.pv. 2x/wk.  on 400  mg/mnth.once dis. stabilisat.noted.  Prim.& second.amenorrh: Second.amenorrh: Admin.8 wks.
       Use low.effect.dos.for short.durat. Miss.dos: Admin. as soon as   Contraindications: Undiagn.vag./urin.tract bleed./breast pathol-  aft.last menstrual period. To induc. bleed.admin estrog.(eg estra-
       rememb. Avoid doubl.dos. Addit. of progestagen not recomm.  ogy, thrombophlebit./hist. thereof., sev.liv.funct.impairm.  diol valerate 20 mg IM on 1  day of treatm.& 10 mg IM on 14  day)
                                                                                            th
                                                                              st</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page339.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page335.html">335</a>&nbsp;&nbsp;&nbsp;<a href="page336.html">336</a>&nbsp;&nbsp;&nbsp;<a href="page337.html">337</a>&nbsp;&nbsp;&nbsp;<a href="page338.html">338</a>&nbsp;&nbsp;&nbsp;<a href="page339.html">339</a>&nbsp;&nbsp;&nbsp;<a href="page340.html">340</a>&nbsp;&nbsp;&nbsp;<a href="page341.html">341</a>&nbsp;&nbsp;&nbsp;<a href="page342.html">342</a>&nbsp;&nbsp;&nbsp;<a href="page343.html">343</a>&nbsp;&nbsp;&nbsp;<a href="page344.html">344</a>&nbsp;&nbsp;&nbsp;<a href="page345.html">345</a>
             </td>
             <td width="35%"><a href="page341.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page341.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
